Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
Molecular Devices is hiring 3 roles related to this product
FENOFIBRATE (fenofibrate) by Molecular Devices is peroxisome proliferator-activated receptor alpha agonists [moa]. Approved for type 2 diabetes mellitus, coronary heart disease morbidity, mortality in a large and 1 more indications. First approved in 2008.
Drug data last refreshed 1h ago
Peroxisome Proliferator-activated Receptor alpha Agonists
Peroxisome Proliferator Receptor alpha Agonist
Worked on FENOFIBRATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Fenofibrate for Prevention of DR Worsening
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMolecular Devices is hiring 3 roles related to this product